Skip to main content
logo
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
22.68
+1.12 (5.19%)
At close: Jul 30, 2026, 4:00 PM EDT
22.90
+0.22 (0.97%)
After-hours: Jul 30, 2026, 7:34 PM EDT

Monte Rosa Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
42.95123.6775.62---
Revenue Growth
-73.07%63.54%----
Gross Profit
42.95123.6775.62---
Operating Income
-148.28-54.21-81.11-143.31-112.38-72.88
Net Income
-130.01-38.63-72.7-135.35-108.5-73.96
Earnings Per Share
-1.48-0.46-0.98-2.63-2.30-2.96
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
666.22377.1372.15232.41262.83346.07
Total Debt
39.0639.1942.7246.04470
Net Cash (Debt)
627.16337.91329.43186.37215.83346.07
Net Cash Growth
120.67%2.57%76.76%-13.65%-37.64%729.93%
Net Cash Per Share
7.174.074.463.634.5713.84

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-14.68-22.842-43.8-92.47-59.36
Capital Expenditures
-4.98-4.7-3.99-19.04-12.91-9.73
Free Cash Flow
-19.66-27.538.01-62.84-105.38-69.1
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-345.21%-43.83%-107.26%---
Pretax Margin
-307.04%-32.12%-92.74%---
Profit Margin
-302.69%-31.23%-96.14%---
FCF Margin
-45.76%-22.23%50.26%---

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
--11.23---
PS Ratio
44.618.315.64---